Medistri, a provider of contract sterilization, laboratory, packaging validation, manufacturing, logistics, and consulting services for the healthcare industry, has become a member of Swiss Medtech, the association representing the Swiss MedTech sector.

BioLizard has appointed Dr. Alexander Scheer as Chief Scientific Officer, adding 25+ years of translational R&D leadership across biotech and pharma in November 2025. He will help scale BioLizard’s multi-omics and AI-driven strategy, strengthening work in biomarkers, precision medicine, and therapeutic innovation.  

LubioScience and Mabtech have entered into a strategic partnership to strengthen the availability of high-quality immunoassay solutions for research and diagnostics customers in Switzerland. The collaboration combines Mabtech’s internationally recognised ELISA, EYRAplex, ELISpot and FluoroSpot technologies with LubioScience’s established distribution network and local scientific support, aimin

BaseLaunch selects Umlaut.bio for support thereby raising the pre-seed funding to a total of ~EUR 3m Prof. Dr. Oliver Distler, Universitätspital Zurich,  joins Umlaut.bio’s SAB catalyzing the development of the systemic sclerosis franchise Prof. Dr. Tsutomu Suzuki, University Tokio, completes the SAB, underpinning the worldwide leadership in tRNA science

NewBiologix S.A., a biotechnology company advancing recombinant adeno-associated virus (rAAV) production through next-generation clonal HEK293 cell line technology, today announced publication of peer-reviewed data in Biotechnology Reports (Vol. 49, March 2026). Paper reports two-fold higher full-to-empty rAAV ratio using NBX1P01 compared to a leading commercial HEK293 cell line.

Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform structure-based drug design